U.S. markets closed

Cytosorbents Corporation (CTSO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.62-0.01 (-0.13%)
At close: 4:00PM EDT
7.75 +0.13 (1.71%)
After hours: 05:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.63
Open7.69
Bid7.57 x 800
Ask7.62 x 800
Day's Range7.47 - 7.72
52 Week Range7.13 - 11.68
Volume118,773
Avg. Volume246,692
Market Cap330.093M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Here's Why Cytosorbents Is Up 17% Today
    Motley Fool

    Here's Why Cytosorbents Is Up 17% Today

    Shares of Cytosorbents Corporation (NASDAQ: CTSO) jumped 17.3% on Tuesday, spurred higher by news that the Investigational Device Exemption (IDE) request for its DrugSorb-ATR Antithrombotic Removal system has been approved by the U.S. Food and Drug Administration, allowing clinical trials of the device to move forward. Cytosorbents' DrugSorb-ATR Antithrombotic Removal device just cleared another regulatory hurdle. Exempt from certain other steps that some medical devices must go through, the company can now begin testing the device, which allows patients undergoing heart bypass surgeries to curb the amount of blood-thinning drug ticagrelor in the bloodstream during and after the procedure.

  • CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
    Benzinga

    CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

    CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery. This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020. STAR-T will enroll up to 120 patients, and enrollment is expected to begin soon. The study's primary endpoint will evaluate whethe

  • Here's Why We're Not At All Concerned With Cytosorbents' (NASDAQ:CTSO) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not At All Concerned With Cytosorbents' (NASDAQ:CTSO) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...